Form 8-K - Current report:
SEC Accession No. 0001628280-23-007294
Filing Date
2023-03-09
Accepted
2023-03-09 16:06:01
Documents
14
Period of Report
2023-03-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mnlo-20230309.htm   iXBRL 8-K 34458
2 EX-99.1 vyne-20230309q4x2022exx991.htm EX-99.1 204876
6 imagea.jpg GRAPHIC 33776
  Complete submission text file 0001628280-23-007294.txt   446972

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnlo-20230309.xsd EX-101.SCH 2026
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnlo-20230309_lab.xml EX-101.LAB 25136
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnlo-20230309_pre.xml EX-101.PRE 13154
8 EXTRACTED XBRL INSTANCE DOCUMENT mnlo-20230309_htm.xml XML 11267
Mailing Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 23719738
SIC: 2834 Pharmaceutical Preparations